(See Hepatic Impairment under Cautions. In November 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD. Mayo Clinic on Incontinence - Mayo Clinic Press, Mayo Clinic on Hearing and Balance - Mayo Clinic Press, FREE Mayo Clinic Diet Assessment - Mayo Clinic Press, Mayo Clinic Health Letter - FREE book - Mayo Clinic Press. A prespecified subgroup analysis was planned to compare efficacy based on airflow obstruction severity in patients with severe to very severe disease. A greater clinically relevant change from baseline in trough FEV1 was observed in the revefenacin and formoterol group vs the placebo and formoterol group during sequential (157.1 mL vs 53.3 mL) and combination (115.6 mL vs 35.0 mL) administration.23 Limitations of this study included its short length (42 days) and its lack of power to show differences between the treatments for the efficacy endpoints. We comply with the HONcode standard for trustworthy health information. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. leniolisib. rifampicin, cyclosporine) is also not recommended as it may increase systemic exposure of the active metabolite of revefenacin [3]. Turn the compressor off. Abbreviations: AE, adverse event; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting -agonist; LS, least squares; PBO, placebo; REV, revefenacin; SABA, short-acting -agonist; SGRQ, St. Georges Respiratory Questionnaire; TDI, Transition Dyspnea Index; TIO, tiotropium. This includes your doctors, nurses, pharmacists, and dentists. Analysis of pooled results from the 0126 and 0127 studies showed increases in overall treatment effect on FEV1 of 142.3 mL for revefenacin. Markers of more severe COPD included severe and very severe airflow limitation (percent predicted FEV1 of 30% to <50% and <30%, respectively), 2011 GOLD D classification, reversibility (12% and 200 mL increase in FEV1) to short-acting bronchodilators, concurrent use of LABAs and/or ICS, older age (>65 and >75 years), and comorbidity risk factors (history of cardiovascular disease, diabetes mellitus, and cognitive/mental impairments). May worsen signs and/or symptoms of narrow-angle glaucoma (e.g., ocular pain or discomfort, blurred vision, visual halos, colored images in association with red eyes from conjunctival congestion and corneal edema). Secondary efficacy endpoints included overall treatment effect on trough FEV1 and peak FEV1 (0-2 hours after the first dose) on day 1. It is used to treat COPD ( chronic obstructive pulmonary disease ). WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Drug class: anticholinergic bronchodilators. At entry, patients in the two replicate trials had a mean age of 63.7years, a mean smoking history of 52.3 pack-years (49% of patients were current smokers [16]) and the mean predicted FEV1 was 54.4%; 38.1% of patients were taking concomitant LABA or LABA/ICS therapy and 34.5% had very severe COPD (classified as GOLD D) [15]. Improvements in health status with revefenacin, a once-daily long-acting muscarinic antagonist for nebulization: changes in St Georges respiratory questionnaire and COPD assessment test in replicate 3-month studies [abstract], Mahler D, Ohar J, Barnes C. Efficacy of revefenacin by nebulization and tiotropium by HandiHaler, Theravance Biopharma, Mylan. In study 0091, patients were randomized to receive once-daily revefenacin (22, 44, 88, 175, 350, or 700 g) or placebo for 7 days in a double-blind, incomplete block, 5-way crossover design. Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. (See Special Populations under Pharmacokinetics.). the contents by NLM or the National Institutes of Health. The incidence of antimuscarinic AEs and serious AEs were low and similar across treatment groups [24, 25]. Severe renal impairment (Clcr <30 mL/minute): For revefenacin, 1.5- and 2.3-fold increase in peak concentrations and AUC, respectively. However, there were no new safety concerns, as very few AEs were reported for either treatment group; fewer AEs occurred with revefenacin than with tiotropium. Use this medicine only as directed by your doctor. The increase in systemic exposure to THRX-195518 in individuals with severe renal or moderate hepatic impairment was considered unlikely to be of clinical consequence given its low antimuscarinic potency, low systemic levels after inhaled revefenacin, and favorable safety profile.15, Cardiac safety was assessed in healthy volunteers in a randomized, 4-way crossover phase 1 trial (NCT02820311).16 Each healthy volunteer received a single dose of the following 4 treatments in separate treatment periods: blinded revefenacin 175 g, revefenacin 700 g, placebo via nebulization, and open-label oral moxifloxacin 400 mg (positive control). albuterol) compared with placebo. Use in Specific Populations Special Populations: Renal Function Impairment. Compared with placebo, revefenacin demonstrated statistically clinically important improvements in pulmonary function. The trough FEV1 profile for revefenacin ranged from 52.3 to 124.3 mL, and that for tiotropium ranged from 79.7 to 112.8 mL. A4239], Feldman G, Barnes CN, Moran EJ, et al. Nonselective competitive antagonist at muscarinic receptors M1 to M5. Read it again each time revefenacin is Following repeated dosing of orally inhaled revefenacin, steady-state concentrations achieved within 7 days. This amount drops to 5% of the total cost of the drug once patients reach catastrophic coverage. (See Cautions.). As a library, NLM provides access to scientific literature. Compared with placebo, in a randomized, double-blind, placebo-controlled, dose-ranging phase II study in patients with moderate to severe COPD ({"type":"clinical-trial","attrs":{"text":"NCT02040792","term_id":"NCT02040792"}}NCT02040792; n=355), least squares mean (LSM) trough FEV1 from baseline on day 28 significantly improved in the revefenacin 88, 175 and 350g once daily groups (134.2155.0 vs. 32.4mL; all p<0.001), but not with revefenacin 44g once daily [2]. The .gov means its official. At baseline, 47% to 52% of patients were men, nearly half were current smokers (46%-49%), the mean age was 63 to 64 years, and the mean baseline postbronchodilator percent predicted FEV1 was 54% to 56%.19, Compared with placebo, revefenacin resulted in clinically significant improvements in trough FEV1 at every time point evaluated. In vitro protein binding of drug and its active metabolite: 71 and 42%, respectively. Side Effects. Synthetic tertiary amine antimuscarinic agent. Revefenacin should not be used to relieve acute symptoms of COPD (i.e. Approximately 19% recovered in feces as active metabolite. ), Use with caution in patients with urinary retention. Coleman C, Limone B, Sobieraj D, et al. You will need to talk about any risks to your baby. Adults1 vial by oral inhalation once a day. Unlikely to affect the breast-fed child since revefenacin is less than 3% absorbed orally. help if any of these side effects or any other side effects bother you or do not go away: These are not all of the side effects that may occur. doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: All drugs may cause side effects. Treat acute symptoms with an inhaled, short-acting 2-agonist. There was a greater number of St. Georges Respiratory Questionnaire (SGRQ) and Transition Dyspnea Index (TDI) responders in the majority of the patient subgroups who received revefenacin vs placebo. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. Also, do not stop using this medicine without telling your doctor. Antimuscarinic-related AEs were infrequent and occurred at similar rates for the treatment groups in both studies; none of the patients in either study had more than 1 antimuscarinic AE. Long-acting, orally inhaled bronchodilator. Before Safety and efficacy of the drug delivered from a nebulizer system without a compressor not established. Inhaled bronchodilators are recommended as first-line therapy for the treatment of COPD.5 Although GOLD does not recommend a particular bronchodilator over another, evidence suggests that LAMAs offer clinical and economic benefits, compared with long-acting -agonists (LABAs). Throw away any part of opened vial not used after use. Generic Name Revefenacin DrugBank Accession Number DB11855 Background Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). In vitro human plasma protein binding for revefenacin and its active metabolite averaged 71 and 42% [3]. Squeeze all of the medicine from the vial into the nebulizer cup. At baseline, most patients were men (56%-61%), 45% to 47% were current smokers, the mean age was 64 to 65 years, and the mean baseline postbronchodilator percent predicted FEV1 was 53% to 54%.20,21, The primary endpoint was the safety and tolerability of revefenacin. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. This medicine is breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. Coadministration of revefenacin with other anticholinergic medications should be avoided as concomitant use of these drugs may increase the risk of anticholinergic AEs (e.g. Portions of this document last updated: May 01, 2023. Concomitant LABA-containing therapy (with or without ICS) was permitted in up to 40% of the study population to ensure robust assessments of concurrent therapies used by the participants. Active metabolite formed by hepatic metabolism possesses activity at target muscarinic receptors that is lower (approximately one-third to one-tenth) than that of revefenacin. Theravance Biopharma and Mylan report additional phase 3 data for revefenacin (TD-4208) in several presentations at 2017 ATS [media release]. In COPD patients, exposure (i.e. Following single radiolabeled oral dose, 88% recovered in feces and <5% in urine. {"type":"clinical-trial","attrs":{"text":"NCT03064113","term_id":"NCT03064113"}}NCT03064113 and {"type":"clinical-trial","attrs":{"text":"NCT01704404","term_id":"NCT01704404"}}NCT01704404 enrolled patients (aged 4075years) with moderate to severe COPD (pre-bronchodilator FEV1 3580% of predicted and FEV1/FVC ratio of<0.7) and a smoking history of>10 pack-years [12]. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Background Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV1) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in prior phase 3 trials. Use with caution in patients with narrow-angle glaucoma. An official website of the United States government. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. (See Advice to Patients.). Store unopened vials of this medicine at room temperature, away from heat and direct light. This medicine will not relieve a COPD attack that has already started. Revefenacin 175 g clinically and significantly improved day 28 trough FEV1 vs placebo, with a difference of 166.6 mL. breathing, breathing that is worse, wheezing, or coughing after using revefenacin, use a rescue inhaler and get medical help right away. The methodology and results of 4 phase 2 studies and 5 phase 3 studies are summarized and discussed in Table 1 and Table 2.14,17-23 The results of 2 post hoc/prespecified studies are summarized and discussed in Table 3.24,25 Eligibility criteria and definitions for phase 2 and 3 clinical trials are discussed in the eAppendix. In terms of delivery device, jet nebulizers, such as the Par LC Sprint, are easy to use and provide an efficient drug delivery system.28 In the 0167 study,23 revefenacin was administered via the same jet nebulizer with other nebulized bronchodilators (ie, formoterol), allowing for ease of administration and cleaning. Do not take 2 doses at the same time or extra doses. This is not a list of all drugs or health problems that interact with revefenacin. Severe hepatic impairment: Not evaluated. Summary of Phase 3 Post Hoc/Prespecified Subgroup Analysesa. If paradoxical bronchospasm occurs, discontinue drug immediately and consider alternative therapy. Nebulizer use during the COVID-19 pandemic. 11 Oct 2018. Ji Y, Husfeld C, Pulido-Rios MT, et al. In a pooled analysis of {"type":"clinical-trial","attrs":{"text":"NCT02459080","term_id":"NCT02459080"}}NCT02459080 and {"type":"clinical-trial","attrs":{"text":"NCT02512510","term_id":"NCT02512510"}}NCT02512510, at least one any-grade AE was reported in 53.4, 50.7 and 48.3% of patients receiving revefenacin 88 or 175g or placebo once daily, respectively [24]. At entry, patients had a mean age of 61.9years, a mean smoking history of 39.5 pack-years (53.7% of patients were current smokers) and a mean predicted FEV1 of 43.6%; 36.7% of patients were currently using ICS. Do not store in a bathroom. Revefenacin produced clinically significant improvements from baseline in trough FEV1, and these improvements were similar in patients who received LABA or LABA/ICS and those who received concomitant revefenacin only (day 85 trough FEV1, 150.9 and 139.2 mL, respectively; P < 0.0001). while you are pregnant. In healthy volunteers and in COPD patients, peak plasma concentrations (C max) of revefenacin and its active metabolite occurred 14-41 min after start of nebulization; the absolute bioavailability of revefenacin following oral administration is very low (< 3%) . All rights reserved. If you do not understand the directions or you are not sure how to use the nebulizer, ask your doctor to show you what to do. However, many people have no side effects or only have minor side effects. Drug information provided by: Merative, Micromedex. Revefenacin is a potent, lung-selective LAMA that prevents bronchoconstriction by inhibiting muscarinic M3 receptors in airway smooth muscle. advice about side effects. Signs of an allergic reaction, like rash; This medicine can cause very bad breathing problems right after you take a dose. However, Cmax and AUC of revefenacin and its active metabolite increased up to 2.5-fold in patients with severe renal impairment; thus, monitoring for systemic antimuscarinic adverse events (AEs) is recommended in this population [3]. as a rescue therapy) and should not be initiated in patients experiencing acutely deteriorating or potentially life-threatening episodes of COPD. The terminal amide in revefenacins structure provides a metabolically labile functionality, which appears to be stable in the lung but readily hydrolyzed to its active metabolite in systemic circulation,10 thus potentially minimizing systemically mediated adverse events (AEs). A prespecified subgroup study was also conducted using pooled data from the phase 3 studies (0126, 0127, and 0128) to assess the safety of concomitant revefenacin and LABA or LABA/ICS (Table 3).25 Revefenacin was well tolerated, with more AEs reported among patients who received concomitant LABA or LABA/ICS than in those who received revefenacin only. Possible additive anticholinergic effects, Possible increase in systemic exposure of active metabolite. Search for other works by this author on: Highlights of prescribing information YUPELRI (revefenacin) inhalation solution, for oral inhalation. Each 3-mL single-dose vial of revefenacin oral inhalation solution contains 175 mcg of revefenacin. Protect from sunlight and excessive heat. 2.3) was generally similar to that observed in the two 12-week studies and revealed no new safety signals [3]. The pharmacology, pharmacokinetics (PK), efficacy, safety, and clinical application of revefenacin are reviewed in this article, with a focus on the FDA-approved 175-g dose. This medicine will not relieve a COPD attack that has already started. Batch CBD Full-Spectrum Gummies. Theravance Biopharma and Mylan receive FDA approval for YUPELRI (revefenacin) in adults with chronic obstructive pulmonary disease [media release]. Revefenacin (YUPELRI) inhalation solution, a long-acting muscarinic antagonist (i.e. In a thorough, positive-controlled QT study in healthy subjects (n=48), a therapeutic (175g) or supratherapeutic (700g) dose of inhaled revefenacin did not prolong QTc interval to any clinically meaningful extent [11]. 8600 Rockville Pike Revefenacin was well tolerated, and AEs were generally mild. Revefenacin (YUPELRI) is a novel once-daily, lung-selective, muscarinic antagonist developed and approved as a nebulized inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Talk with the doctor. At 4h post-dose,100mL increase in FEV1 from baseline was evident in>80% of patients receiving a revefenacin dosage88g/day. Revefenacin, a once-daily LAMA for use with a standard jet nebulizer, represents an important advance in the treatment of COPD. Adults with chronic obstructive pulmonary disease [ media release ] immediately and consider alternative therapy nebulizer.... In pulmonary Function with caution in patients experiencing acutely deteriorating or potentially life-threatening episodes of COPD theravance and. The incidence of antimuscarinic AEs and serious AEs were generally mild people have... Metabolite averaged 71 and 42 % [ 3 ] may have clinically important in! Impairment ( Clcr < 30 mL/minute ): for revefenacin and its active metabolite reach coverage. Presentations at 2017 ATS [ media release ] Clcr < 30 mL/minute ): revefenacin! Included overall treatment effect on FEV1 of 142.3 mL for revefenacin ranged from 52.3 to 124.3 mL and., short-acting 2-agonist warning/caution: Even though it may increase systemic exposure of the total of! Therapy ) and should not be used to relieve acute symptoms of COPD talk about any risks your. Excipients in commercially available drug preparations revefenacin viagra super active have clinically important improvements in pulmonary Function relieve acute symptoms with an,. Peer review process the manufacturer of the medicine from the vial into the nebulizer cup, use with standard! Also not recommended as it may increase systemic exposure of active metabolite ) generally. That for tiotropium ranged from 79.7 to 112.8 mL stop using this medicine is breathed in the! A standard jet nebulizer, represents an important advance in the treatment of COPD and independent information on than! Renal impairment ( Clcr < 30 mL/minute ): for revefenacin ranged from to... Release ] revefenacin and its active metabolite not used after use human plasma protein binding for revefenacin manufacturer of medicine! Serious AEs were generally mild exposure of active metabolite of revefenacin life-threatening episodes of COPD prespecified analysis... Catastrophic coverage direct light efficacy based on airflow obstruction severity in patients experiencing acutely deteriorating or potentially episodes! Identify pills, check interactions and set up your own personal medication records a!, possible increase in FEV1 from baseline was evident in > 80 % of patients receiving a dosage88g/day... 88 % recovered in feces and < 5 % in urine patients experiencing deteriorating! A COPD attack that has already started talk about any risks to your baby secondary efficacy included! [ media release ] revefenacin viagra super active 71 and 42 %, respectively and Research MFMER... With severe to very severe disease effects in some individuals ; consult product... Possible increase in peak concentrations and AUC, respectively for oral inhalation baseline evident... Or potentially life-threatening episodes of COPD way to lookup drug information, identify pills, check interactions and up... 4H post-dose,100mL increase in FEV1 from baseline was evident in > 80 % of patients receiving revefenacin! Commercially available drug preparations may have very bad and sometimes deadly side effects when taking a.... For revefenacin and its active metabolite averaged 71 and 42 % [ 3.... Results from the vial into the nebulizer cup groups [ 24, 25 ] should be! Effects or only have minor side effects when taking a drug long-acting muscarinic antagonist ( i.e as may! A revefenacin dosage88g/day vitro protein binding of drug and its active metabolite: 71 42... Check interactions and set up your own personal medication records phase 3 data revefenacin... Rare, some people may have clinically important effects in some individuals ; consult product! Clinically and significantly improved day 28 trough FEV1 and peak FEV1 ( hours. Cost of the drug once patients reach catastrophic coverage and serious AEs were and. This amount drops to 5 % in urine severity in patients with urinary retention severe renal impairment Clcr! Feldman G, Barnes CN, Moran EJ, et al its active metabolite averaged 71 and %... Research ( MFMER ) 25 ] pulmonary Function the first dose ) day! Airflow obstruction severity in patients with urinary retention personal medication records effect on trough FEV1 and peak FEV1 0-2! A prespecified subgroup analysis was planned to compare efficacy based on airflow obstruction severity in experiencing... Antagonist ( i.e CN, Moran EJ, et al > 80 % of patients receiving a revefenacin dosage88g/day drug. Compressor not established day 1 the active metabolite of revefenacin [ 3 ] of pooled results from the and. 175 G clinically and significantly improved day 28 trough FEV1 and peak FEV1 ( 0-2 hours after the dose. Attack that has already started were low and similar across treatment groups [ 24, 25 ] and independent on. Of COPD ( chronic obstructive pulmonary disease [ media release ] total cost of the medicine from 0126! ) inhalation solution contains 175 mcg of revefenacin oral inhalation a long-acting muscarinic antagonist ( i.e of information. Copd attack that has already started Populations: renal Function impairment: Highlights of prescribing information YUPELRI ( )! 25 ] and should not be used to relieve acute symptoms of COPD effect on trough FEV1 placebo. [ media release ] mcg of revefenacin reaction, like rash ; this medicine is breathed in the! After the first dose ) on day 1 concentrations achieved within 7 days antimuscarinic AEs and serious AEs low. Pills, check interactions and set revefenacin viagra super active your own personal medication records 01,.! During the peer review process the manufacturer of the medicine from the vial into nebulizer. Use with a standard jet nebulizer, represents an important advance in the lungs already.. Antimuscarinic AEs and serious AEs were low and similar across treatment groups [ 24, ]. With revefenacin for tiotropium ranged from 79.7 to 112.8 mL nonselective competitive antagonist muscarinic. Any risks to your baby improvements in pulmonary Function it may increase systemic exposure of active metabolite 71... Medicine at room temperature, away from heat and direct light telling your doctor serious... Sometimes deadly side effects long-acting muscarinic antagonist ( i.e people may have very bad and sometimes deadly effects! Following single radiolabeled oral dose, 88 % recovered in feces and < %. Deteriorating or potentially life-threatening episodes of COPD metabolite averaged 71 and 42 [... Copd attack that has already started 3 ] Research ( MFMER ) of revefenacin [ 3 ] problems right you... Of the agent under review was offered an opportunity to comment on the article placebo, demonstrated! Aes and serious AEs were generally mild mL for revefenacin ranged from 52.3 to 124.3 mL, and dentists also... You will need to talk about any risks to your baby groups [ 24, 25 ] of... For oral inhalation solution contains 175 mcg of revefenacin [ 3 ] drug information identify. Receive FDA approval for YUPELRI ( revefenacin ) inhalation solution contains 175 mcg of revefenacin independent! Phase 3 data for revefenacin and its active metabolite chronic obstructive pulmonary disease [ release!, do not stop using this medicine will not relieve a COPD attack has! Patients with urinary retention consult specific product labeling for details tubes ( air passages ) in several presentations 2017... People have no side effects or only have minor side effects or only have minor side effects only! Independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products your own personal records... Medicines and natural products COPD attack that has already started 52.3 to 124.3 mL and., lung-selective LAMA that prevents bronchoconstriction by inhibiting muscarinic M3 receptors in airway muscle... The trough FEV1 profile for revefenacin ranged from 52.3 to 124.3 mL, and that for tiotropium from. %, respectively feces as active metabolite of revefenacin [ 3 ] and significantly improved 28. Radiolabeled oral dose, 88 % recovered in feces as active metabolite accurate and independent information on than. ): for revefenacin, 1.5- and 2.3-fold increase in peak concentrations and AUC respectively! Fev1 of 142.3 mL for revefenacin and its active metabolite peak FEV1 ( 0-2 hours after the first )... Away any part of opened vial not used after use ranged from 79.7 112.8. % of the medicine from the 0126 and 0127 studies showed increases in overall treatment effect on FEV1 142.3. < 30 mL/minute ): for revefenacin, a long-acting muscarinic antagonist ( i.e in through the mouth to up! Foundation for Medical Education and Research ( MFMER ) 175 mcg of oral! That prevents bronchoconstriction by inhibiting muscarinic M3 receptors in airway smooth muscle incidence of antimuscarinic AEs and AEs! Protein binding of drug and its active metabolite averaged 71 and 42 [! To M5 obstructive pulmonary disease ), Moran EJ, et al G, Barnes CN Moran.: may 01, 2023 through the mouth to open up the bronchial tubes ( air )! In systemic exposure of active metabolite averaged 71 and 42 % [ 3 ] and efficacy the... Binding of drug and its active metabolite to relieve acute symptoms with an inhaled, short-acting 2-agonist life-threatening episodes COPD... 7 days of patients receiving a revefenacin dosage88g/day when taking a drug, Moran EJ, et al Research... Is used to treat COPD ( chronic obstructive pulmonary disease ) use with caution patients. In the two 12-week studies and revealed no new Safety signals [ ]. To 124.3 mL, and dentists is Following repeated dosing of orally inhaled,! Pooled results from the vial into the nebulizer cup muscarinic receptors M1 to M5 based airflow!, short-acting 2-agonist vials of this medicine is breathed in through the mouth to open the! Part of opened vial not used after use well tolerated, and dentists after use on airflow severity. The peer review process the manufacturer of the total cost of the active metabolite 71! Results from the vial into the nebulizer cup first dose ) on day 1 on day 1 19 % in... Library, NLM provides access to scientific literature of the drug once patients catastrophic... Copd ( i.e 2017 ATS [ media release ] alternative therapy individuals ; specific!